Advertisement
Neoadjuvant chemotherapy is less likely to benefit black women with breast cancer than those in other racial and ethnic groups

Early Chemo Less Likely to Help Black Breast Cancer Patients

0
More research needed to explain why outcomes differ among black, Hispanic, and Asian women
More frequent monitoring may be required when patients are taking both acenocoumarol and levofloxacin due to the possibility of an adverse interaction

Interaction Described Between Acenocoumarol, Levofloxacin

0
Probable interaction described in five patients, all of whom had atrial fibrillation
Implementation of a new model of care can improve outcomes of care in medical and surgical units

New Model of Inpatient Care Can Improve Outcomes

0
Model aims to up interprofessional collaboration, data-driven decisions, provide leadership
Teens who use abuse prescription drugs such as opioids are more likely to have sex or to participate in risky sexual behaviors

Abuse of Prescription Drugs Ups Sexual Risks for Teens

0
Those taking these drugs with no prescription more likely to have multiple partners, forgo condom use
Alecensa (alectinib) has been approved by the U.S. Food and Drug administration to treat anaplastic lymphoma kinase-positive non-small-cell lung cancer

FDA Approves Alecensa for ALK-Positive NSCLC

0
Drug is designed to block the effects of the ALK protein
Patients with rheumatoid arthritis have increased herpes zoster risk with older age and higher prednisone dose

Herpes Zoster Risk in RA Up With Older Age, Prednisone Dose

0
HZ risk comparable after initiation of TNFi, non-TNFi, and conventional synthetic DMARDs
Seven behaviors should be implemented to improve the art of medicine

Seven Behaviors Suggested to Improve ‘Art of Medicine’

0
Seven behaviors promote more consistent practice of interpersonal aspects of medicine
Pharmaceutical industry-sponsored studies are more likely to report favorable estimates in cost-effectiveness analysis of drugs used in breast cancer treatment

Industry-Led Oncology Trials May Inflate Cost-Effectiveness

0
Breast cancer cost-effectiveness analyses show favorable estimates with industry funding
For patients with non-small-cell lung cancer

Toxic Skin Effects Common With EGFR-TKI Use in NSCLC

0
Afatinib therapy linked to earlier paronychia onset; more dermatological visits for skin toxic effects
Postmenopausal women with hormone receptor-positive ductal carcinoma in situ have similar recurrence rates of disease whether they take tamoxifen or the aromatase inhibitor anastrozole after surgery

SABCS: Tamoxifen, Anastrozole Both Prevent Recurrence in DCIS

0
However, side effects differ for the two medications